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Abstract 
BACKGROUND: Bladder cancer is the 9th most frequent cancer worldwide. Ki-67 is immunohistochemistry 
marker that is predictive of cancer cell proliferation. The expression of Ki-67 is associated with poor prognosis in 
several types of malignancy, yet the value of Ki-67 as the prognostic factor in bladder cancer remains 
controversial.  
AIM: This study is aimed to investigate the association between Ki-67 expression with muscle-invasive bladder 
cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC). 
METHODS: This was a case-control study with a retrospective design. The study was conducted at the 
Department of Pathology, University of Sumatera Utara, Indonesia. Samples were paraffin blocks from patients 
diagnosed with bladder cancer and agreed to be put in the study. The samples were stained with 
Immunohistochemistry Staining (IHC), and then we quantitatively counted the number of the Ki-67 stained 
nucleus on a microscope. 
RESULTS: A total of 54 samples were obtained in this study. Samples consisted of 27 samples with NMIBC and 
27 samples with MIBC. The cut-off point was 20%, we found 17 patients with MIBC and 14 patients with NMIBC 
presented with biomarker > 20%. Biomarker ≤ 20% was found in 10 patients with MIBC and 13 patients with 
NMIBC. On statistical analysis with Chi-Square test, no significant association found (p = 0.583) between KI-67 
and muscle - invasiveness with OR of 1.579, 95% CI (0.533-4.678). 
CONCLUSION: There is no association between expression of Ki-67 and muscle invasiveness in bladder cancer. 
 
 
 
 
Introduction 
 
Bladder cancer is a type of neoplasia in 
which the cell aligning the bladder lost its ability to 
control growth and cell division. Worldwide, bladder 
cancer ranked 9
th 
commonly found neoplasia [1]. 
There are two known histopathological staging, 
non-muscle invasive bladder cancer (NMIBC), in 
which the mass was limited to mucous with no muscle 
involvement, and muscle-invasive bladder cancer 
(MIBC).  
Majority of cases found was NMIBC [1][2]. 
Although this type of cancer can be managed easily 
by trans-urethral resection, the recurrence rate was 
15%-75%, with 10% of cases progress into MIBC. 
MIBC tend to have a poor prognosis. It is imperative 
to develop an early diagnosis, as well as appropriate 
treatment in a patient with bladder cancer [3]. 
Immunohistochemistry is an established 
method that supports histopathologic assessment in 
the diagnosis of various benign and malignant 
diseases. In 1982, Nathrath et al. were the first to 
experiment on bladder cancer paraffin sample and 
documenting a set of keratin and carcinoembryonic 
antigen [3]. Since then, the prognostic value of 
immunohistochemistry marker becomes important. In 
the last two decades, immunohistochemistry 
evaluation, specifically regarding cell cycle and 
apoptosis, was intensively pursued to obtain a 
better understanding of prognosis in patient with 
bladder cancer. A prognostic biomarker is essential 
in which they can provide information on disease 
progression, regardless of intervention. Two types of 
prognostic biomarker were recognised, the biomarker 
which can give information of recurrence and 
biomarker which contain information of disease 
progression (progression-free survival). A predictive 
biomarker can provide information about the effect of 
an intervention, as well as able to be used as targeted 
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therapy [4]. Ki-67 is immunohistochemistry marker 
known to be present on an actively proliferating cell. 
Evidence has shown that Ki-67 is a predictive factor 
of cancer cell proliferation, expression of Ki-67 
correlate with poor prognosis in several types of 
cancer [5][6]. Nevertheless, the value of 
Ki-67 as the prognostic factor in bladder 
cancer remains controversial [7]; few studies result 
show that Ki-67 can predict progression and 
recurrence, while other studies show no significant 
correlation. One meta-analysis study by Tian et al. 
concludes that Ki-67 expressions correlate 
significantly with recurrence, progressivity, and lower 
survival only in Caucasian [8]. This research aims to 
evaluate the association between Ki – 67 expressions 
with MIBC and NMIBC. 
 
 
Methods 
 
This study was conducted at the 
Department of Pathology, University of Sumatera 
Utara, Indonesia. Samples were obtained from 
bladder cancer patient primary specimen paraffin 
blocks that were analysed in Pathology laboratory in 
2013-2015. The patients have been confirmed 
agreed to be put in the study. Each group contained 
27 samples. Samples were then stained with 
Immunohistochemistry Staining (IHC), and then 
quantitatively count the number of the Ki-67 stained 
nucleus on a microscope. The interpretation was 
made by calculating the amount of stained cell from 
100 tumour cells, with cut-off point 20% as in Otto et 
al. study (≤ 20% counted as "low expression" and > 
20% count as "overexpression") [9]. 
 
 
Results 
 
Fifty-four samples, which consists of 27 
samples with NMIBC and 27 samples with MIBC 
were obtained. Sample characteristics are shown in 
Table 1. 
Table 1: Sample characteristics of NMIBC and MIBC 
 Group  
Variable NMIBC MIBC p value 
 N = 27 N = 27  
Age 56.1 ± 11.43 60.5 ± 9.85 0.413* 
Gender    
Male 25 (92.6%) 23 (85.2%) 0.669* 
Female 2 (7.4%) 4 (14.8%)  
Grading    
High Grade 12 (44.4%) 27 (100%) <0.001* 
Low Grade 15 (55.6%) 0 (0%)  
*Chi-Square Test. 
 
In NMIBC group, the mean age was 56.1 ± 
11.43 years, while in MIBC was 60.5 ± 9.85 years. 
Male (twenty-three in MIBC and twenty-five in 
NMIBC) was more common than female (four in 
NMIBC and two in NMIBC) in both categories. In 
NMIBC group, more than half of samples were low 
grade (55.6%), and 44.4% high grade (p < 0.001). On 
the above table, sample characteristic on both 
groups from age and gender perspective didn't 
show a significant difference (p = 0.669). 
Table 2: KI-67 Test Result on NMIBC and MIBC 
Biomarker 
Group    
NMIBC MIBC p-value OR 95% CI 
 N = 27 N = 27    
KI 67  > 20 
 
17 (63.0%) 14 (51.9%)    
   0.583* 1.579 (0.533-4.678) 
< 20 
 
10 (37.0%) 
 
13   (48.1%) 
 
   
*Chi-Square Test. 
 
We divided biomarker with the cut-off point 
of 20%, Ki-67 > 20% and Ki-67 ≤ 20%. For KI – 67 
> 20%, we found 17 patients with MIBC and 14 
patients with NMIBC. Biomarker ≤ 20% was found in 
10 patients with MIBC and 13 patients with NMIBC. 
On statistical analysis with Chi-Square test, there 
was no significant association (p = 0.583) between 
KI-67 and muscle-invasiveness with OR of 1.579, 95% 
CI (0.533-4.678). 
 
 
Discussion 
 
Usage of the marker in tissue to help 
clinicians decision was successfully done in few 
malignancy cases. In a research conducted by 
Jonat and Arnold, evaluating Ki-67 and its function 
in clinical practice [ 10] significantly proves the 
importance of the utilisation of marker mentioned 
above to detect the proliferation of a tumour. Also 
shown in the research done by Heslin et al. [11],
 
those in patients with soft tissue sarcoma, the 
increase in Ki-67 marker expressions proved as an 
independent prognostic tool to predict the metastasis 
and the mortality of a tumour. Several studies suggest 
the effectivity of Ki-67 as a prognostic marker. 
Ki-67 is one of many biomarkers that can 
be detected by the monoclonal antibody as a 
proliferation marker. The usage of this 
immunohistochemistry is highly useful due to its rapid 
and accurate result to indicate the presence of 
ongoing proliferation rather than a solid tumour [12]
 
In the recent years, studies about proliferation 
biomarkers are high in demand. Studies show that 
Ki-67 correlated significantly with tumour cells of 
bladder cancer, and is capable of calculating the 
prognostic factor of the disease [13]. 
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The value of Ki-67 as a prognostic 
biomarker of urothelial malignancies in urinary tract 
system is depicted in the meta-analysis study 
conducted by Lei et al. [14].
 
Contraries to that, a 
survey was done by Acikalin et al. find that there is 
no statistically significant correlation between the 
expression of Ki-67 and tumour recurrence 
progressivity and mortality [8]. Instead, they detect 
the presence of Ki-67 correlate with tumour size and 
grading. The research above is congruent with the 
fact that our study did not find a statistically 
significant relationship between the presence of Ki-
67 and bladder cancer progression. Several factors 
may have affected the result, such as incomplete 
biomarker data and a limited number of samples due 
to patient’s reluctance to join our study. 
This study concludes that there is no 
association between expression of Ki-67 and 
muscle invasiveness in bladder cancer. This result 
can be used as a reference for further research, as 
biomarker nowadays proved to be valuable in 
clinically to predict prognosis in the patient, as well as 
provide better intervention for the patient with prostate 
cancer. 
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